EMEA-000986-PIP01-10 - paediatric investigation plan

ocriplasmin

Key facts

• Active Substance:
  ocriplasmin
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/267/2010
• PIP number:
  EMEA-000986-PIP01-10
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of symptomatic focal vitreomacular adhesion
• Route(s) of administration:
  Intravitreal use
• Contact for public enquiries:

  ThromboGenics

  [e-mail]; Belgium; Phone: [phone]; Fax: [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  26/11/2010

Decision

P/267/2010: EMA decision of 26 November 2010 on the granting of a product specific waiver for ocriplasmin (EMEA-000986-PIP01-10)

AdoptedReference Number: EMA/703551/2010